Skip to main navigation Skip to search Skip to main content

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: Results of the TARGET study

  • Keith Henry
  • , Robert J. Wallace
  • , Paul C. Bellman
  • , Dorece Norris
  • , Robin L. Fisher
  • , Lisa L. Ross
  • , Qiming Liao
  • , Mark S. Shaefer

Research output: Contribution to journal › Article › peer-review

25   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: Results of the TARGET study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science